Context Therapeutics
CNTX
Context Therapeutics (CNTX) news
Recent news
Context Therapeutics Inc. Q2 basic EPS USD -0.15
AInvest Wire · Aug 5, 2026Context Therapeutics Inc. Q2 net income USD -14.6 million
AInvest Wire · Aug 5, 2026Context Therapeutics announces inducement grant under Nasdaq listing Rule 5635(c)(4)
AInvest Wire · Jun 9, 2026CnTx pact provides economic rights to CT-202 going forward
Context Therapeutics Inc. (Nasdaq: CNTX) has secured economic rights to its investigational bispecific T cell engaging (TCE) antibody, CT-202, moving forward. CT-202 is a Nectin-4 x CD3 TCE bispecific antibody designed to target Nectin-4, a cell surface protein overexpressed in various solid…
AInvest Wire · May 18, 2026CnTx amendment removes future milestone & royalty obligations
AInvest Wire · May 18, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.